Caris Life Sciences and Ontada announced a strategic and multi-faceted collaboration to advance molecular research and cancer care, enhance the healthcare delivery system and ultimately drive precision medicine by supporting life sciences companies in the development of next-gen oncology therapies.
FDA has approved MI Cancer Seek for use as a companion diagnostic to identify patients with cancer who may benefit from treatment with targeted therapies.
ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a multi-year research collaboration wherein Caris is pairing its genomic, transcriptomic, and proteomic profiling, advanced artificial intelligence and machine learning algorithms with ECOG-ACRIN’s research capabilities.
Two major cancer informatics companies—Flatiron Health and Caris Life Sciences—have created a partnership to generate combined biological and clinical real-world evidence datasets that can be used to inform the development of immuno-oncology agents and targeted cancer therapeutics.
Caris Life Sciences and Flatiron Health have partnered to create a multimodal data offering to support and accelerate biopharmaceutical drug development and patient care.
Caris Life Sciences and Xencor, Inc. expanded their collaboration to research, develop, and commercialize novel XmAb bispecific and multi-specific antibodies directed against novel targets, identified and proposed by Caris, for the treatment of patients with cancer.
Caris Life Sciences has formed a partnership with Flatiron Health, a healthtech company that helps cancer centers deliver better care for patients.
